 Previously reported experimental and clinical data suggest that proteasome inhibition may have immunomodulatory activity relevant to graft versus host disease . To explore the safety and activity of carfilzomib in advanced chronic GVHD we conducted a multicenter pilot phase II trial through the Chronic GVHD Consortium . Carfilzomib was administered at 20 mg m

@highlight Once weekly carfilzomib therapy was not well tolerated in patients with advanced chronic GVHD.
@highlight With limited evidence of efficacy we do not recommend this agent for further study in this indication.
